United States· US:80739-812_65724d4c-78ab-4d85-83b5-73b9da5c2cc3
KRAZATI
A adagrasib product containing adagrasib, registered in United States by Mirati Therapeutics, Inc. The same ATC class is registered in 9 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Adagrasib is registered in 9 of 19 countries.
Countries holding a registration under ATC L01XX77 (adagrasib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Adagrasib · ATC L01XX77
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ADAGRASIB
- Manufacturer
- Mirati Therapeutics, Inc
- Country
- United States (US)
- ATC code
- L01XX77
- ATC class
- Adagrasib
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1180739812121 BOTTLE in 1 CARTON (80739-812-12) / 120 TABLET, COATED in 1 BOTTLE
- ndc1180739812181 BOTTLE in 1 CARTON (80739-812-18) / 180 TABLET, COATED in 1 BOTTLE
- ndc1180739-812-12
- ndc1180739-812-18
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Adagrasib in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKRAZATIBristol-Myers Squibb Pharma EEIG, Dublin
- FinlandKRAZATIBristol-Myers Squibb Pharma EEIG
- IrelandKRAZATI 200 mg film-coated tabletsBristol-Myers Squibb Pharma EEIG
- IcelandKrazatiBristol-Myers Squibb Pharma EEIG
- NetherlandsKrazati 200 mg, filmomhulde tabletBristol-Myers Squibb Pharma EEIG
- PolandKrazatiBristol-Myers Squibb Pharma EEIG
- BelgiumKrazati 200 mgBristol-Myers Squibb Pharma
- SwedenKRAZATI 200 mg Filmdragerad tablettBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Krazati
- Liechtenstein · Krazati
- Norway · Krazati
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9978325d-ca18-4bca-b1b9-38af03b5705e GET /v1/drugs/9978325d-ca18-4bca-b1b9-38af03b5705e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "200",
"substance": "ADAGRASIB",
"productndc": "80739-812",
"dosage_form": "TABLET, COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA216340",
"marketing_category": "NDA"
}See everything about adagrasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.